We sat down with Johan Emilsson, the CEO of Sprint Bioscience, to discuss the company's Q1 progress, the outlook for its pipeline and the growing attention the company has attracted following the TREX1 licensing deal with Gilead.

Läs mer på Redeye

Ämnen i artikeln


Sprint Bioscience

Senast

4,39

1 dag %

0,46%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån